2,6-Bis(3,4,5-trihydroxybenzylydene) derivatives of cyclohexanone: novel potent HIV-1 integrase inhibitors that prevent HIV-1 multiplication in cell-based assays

A number of 2,6-bisbenzylidenecyclohexane-1-one derivatives have been synthesized and tested as HIV-1 integrase (IN) inhibitors with the aim of obtaining compounds capable to elicit antiviral activity at non-cytotoxic concentrations in cell-based assays. 3,5-Bis(3,4,5-trihydroxybenzylidene)-4-oxocyc...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Bioorganic & medicinal chemistry 2004-01, Vol.12 (1), p.199-215
Hauptverfasser: Costi, Roberta, Santo, Roberto Di, Artico, Marino, Massa, Silvio, Ragno, Rino, Loddo, Roberta, La Colla, Massimiliano, Tramontano, Enzo, La Colla, Paolo, Pani, Alessandra
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 215
container_issue 1
container_start_page 199
container_title Bioorganic & medicinal chemistry
container_volume 12
creator Costi, Roberta
Santo, Roberto Di
Artico, Marino
Massa, Silvio
Ragno, Rino
Loddo, Roberta
La Colla, Massimiliano
Tramontano, Enzo
La Colla, Paolo
Pani, Alessandra
description A number of 2,6-bisbenzylidenecyclohexane-1-one derivatives have been synthesized and tested as HIV-1 integrase (IN) inhibitors with the aim of obtaining compounds capable to elicit antiviral activity at non-cytotoxic concentrations in cell-based assays. 3,5-Bis(3,4,5-trihydroxybenzylidene)-4-oxocyclohexaneacetic acid (20d) resulted one of the most potent and selective derivatives in acutely infected MT-4 cells (EC50 and CC50 values of 2 and 40 μM, respectively). In enzyme assays with recombinant HIV-1 integrase (rIN), this compound proved able to inhibit both 3′-processing and disintegration with IC50 values of 0.2 and 0.5 μM, respectively. In order to develop a model capable to predict the anti HIV-IN activity and useful to design novel derivatives, we performed a comparative molecular field analysis (CoMFA) like 3-D-QSAR. In our model the ligands were described quantitatively in the GRID program, and the model was optimized by selecting only the most informative variables in the GOLPE program. We found the predictive ability of the model to increase significantly when the number of variables was reduced from 20,925 to 1327. A Q2 of 0.73 was obtained with the final model, confirming the predictive ability of the model. By studying the PLS coefficients in informative 3-D contour plots, ideas for the synthesis of new compounds could be generated. Graphic
doi_str_mv 10.1016/j.bmc.2003.10.005
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_80078673</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0968089603006928</els_id><sourcerecordid>80078673</sourcerecordid><originalsourceid>FETCH-LOGICAL-e289t-d968074227999e0acc428c84c8c46875fbe3834cd67333769f84da9ffa45395e3</originalsourceid><addsrcrecordid>eNpF0d2O1CAUB3BiNO44-gDeGG40mkxHWmgLeqUbdTfZxBv1llA4dZi00AWm2fo2vqk0O2av-MjvnHD4I_SyJPuSlM37474b9b4ihObznpD6EdqUrGEFpaJ8jDZENLwgXDQX6FmMR0JIxUT5FF1kJNqW1xv0t9o1xWcb39Id29VFCvawmODvlg7cn2VYDDh4hw0EO6tkZ4jY91gvevAHuFPOO_iAnZ9hwJNP4BK-uv5VlNi6BL-DipB3B9vZ5EPE6aASngLMD248DclOg9W5uXcZYw3DUHS50mAVo1ric_SkV0OEF-d1i35-_fLj8qq4-f7t-vLTTQEVF6kweVbSsqpqhRBAlNas4pozzTVreFv3HVBOmTZNSyltG9FzZpToe8VqKmqgW_Tmvu8U_O0JYpKjjetrlAN_ipIT0vK1eIteneGpG8HIKdhRhUX-_9QMXp-BiloNfVBO2_jgasqrshXZfbx3kMeaLQQZtQWnwdgAOknjrSyJXKOWR5mjlmvU61WOmv4DIpecGA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>80078673</pqid></control><display><type>article</type><title>2,6-Bis(3,4,5-trihydroxybenzylydene) derivatives of cyclohexanone: novel potent HIV-1 integrase inhibitors that prevent HIV-1 multiplication in cell-based assays</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Costi, Roberta ; Santo, Roberto Di ; Artico, Marino ; Massa, Silvio ; Ragno, Rino ; Loddo, Roberta ; La Colla, Massimiliano ; Tramontano, Enzo ; La Colla, Paolo ; Pani, Alessandra</creator><creatorcontrib>Costi, Roberta ; Santo, Roberto Di ; Artico, Marino ; Massa, Silvio ; Ragno, Rino ; Loddo, Roberta ; La Colla, Massimiliano ; Tramontano, Enzo ; La Colla, Paolo ; Pani, Alessandra</creatorcontrib><description>A number of 2,6-bisbenzylidenecyclohexane-1-one derivatives have been synthesized and tested as HIV-1 integrase (IN) inhibitors with the aim of obtaining compounds capable to elicit antiviral activity at non-cytotoxic concentrations in cell-based assays. 3,5-Bis(3,4,5-trihydroxybenzylidene)-4-oxocyclohexaneacetic acid (20d) resulted one of the most potent and selective derivatives in acutely infected MT-4 cells (EC50 and CC50 values of 2 and 40 μM, respectively). In enzyme assays with recombinant HIV-1 integrase (rIN), this compound proved able to inhibit both 3′-processing and disintegration with IC50 values of 0.2 and 0.5 μM, respectively. In order to develop a model capable to predict the anti HIV-IN activity and useful to design novel derivatives, we performed a comparative molecular field analysis (CoMFA) like 3-D-QSAR. In our model the ligands were described quantitatively in the GRID program, and the model was optimized by selecting only the most informative variables in the GOLPE program. We found the predictive ability of the model to increase significantly when the number of variables was reduced from 20,925 to 1327. A Q2 of 0.73 was obtained with the final model, confirming the predictive ability of the model. By studying the PLS coefficients in informative 3-D contour plots, ideas for the synthesis of new compounds could be generated. Graphic</description><identifier>ISSN: 0968-0896</identifier><identifier>EISSN: 1464-3391</identifier><identifier>DOI: 10.1016/j.bmc.2003.10.005</identifier><identifier>PMID: 14697785</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Anti-HIV Agents - chemistry ; Anti-HIV Agents - pharmacology ; Anti-HIV-1-IN agents ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Biological and medical sciences ; Cell Line, Tumor ; Cyclohexanone derivatives ; Cyclohexanones - chemistry ; Cyclohexanones - pharmacology ; HIV Integrase - metabolism ; HIV Integrase Inhibitors - chemistry ; HIV Integrase Inhibitors - pharmacology ; HIV-1 - drug effects ; HIV-1 - enzymology ; HIV-1 - growth &amp; development ; Humans ; Medical sciences ; Pharmacology. Drug treatments ; Polyhydroxylated aromatics ; QSAR studies ; Virus Replication - drug effects</subject><ispartof>Bioorganic &amp; medicinal chemistry, 2004-01, Vol.12 (1), p.199-215</ispartof><rights>2003 Elsevier Ltd</rights><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.bmc.2003.10.005$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=15382179$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14697785$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Costi, Roberta</creatorcontrib><creatorcontrib>Santo, Roberto Di</creatorcontrib><creatorcontrib>Artico, Marino</creatorcontrib><creatorcontrib>Massa, Silvio</creatorcontrib><creatorcontrib>Ragno, Rino</creatorcontrib><creatorcontrib>Loddo, Roberta</creatorcontrib><creatorcontrib>La Colla, Massimiliano</creatorcontrib><creatorcontrib>Tramontano, Enzo</creatorcontrib><creatorcontrib>La Colla, Paolo</creatorcontrib><creatorcontrib>Pani, Alessandra</creatorcontrib><title>2,6-Bis(3,4,5-trihydroxybenzylydene) derivatives of cyclohexanone: novel potent HIV-1 integrase inhibitors that prevent HIV-1 multiplication in cell-based assays</title><title>Bioorganic &amp; medicinal chemistry</title><addtitle>Bioorg Med Chem</addtitle><description>A number of 2,6-bisbenzylidenecyclohexane-1-one derivatives have been synthesized and tested as HIV-1 integrase (IN) inhibitors with the aim of obtaining compounds capable to elicit antiviral activity at non-cytotoxic concentrations in cell-based assays. 3,5-Bis(3,4,5-trihydroxybenzylidene)-4-oxocyclohexaneacetic acid (20d) resulted one of the most potent and selective derivatives in acutely infected MT-4 cells (EC50 and CC50 values of 2 and 40 μM, respectively). In enzyme assays with recombinant HIV-1 integrase (rIN), this compound proved able to inhibit both 3′-processing and disintegration with IC50 values of 0.2 and 0.5 μM, respectively. In order to develop a model capable to predict the anti HIV-IN activity and useful to design novel derivatives, we performed a comparative molecular field analysis (CoMFA) like 3-D-QSAR. In our model the ligands were described quantitatively in the GRID program, and the model was optimized by selecting only the most informative variables in the GOLPE program. We found the predictive ability of the model to increase significantly when the number of variables was reduced from 20,925 to 1327. A Q2 of 0.73 was obtained with the final model, confirming the predictive ability of the model. By studying the PLS coefficients in informative 3-D contour plots, ideas for the synthesis of new compounds could be generated. Graphic</description><subject>Anti-HIV Agents - chemistry</subject><subject>Anti-HIV Agents - pharmacology</subject><subject>Anti-HIV-1-IN agents</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral agents</subject><subject>Biological and medical sciences</subject><subject>Cell Line, Tumor</subject><subject>Cyclohexanone derivatives</subject><subject>Cyclohexanones - chemistry</subject><subject>Cyclohexanones - pharmacology</subject><subject>HIV Integrase - metabolism</subject><subject>HIV Integrase Inhibitors - chemistry</subject><subject>HIV Integrase Inhibitors - pharmacology</subject><subject>HIV-1 - drug effects</subject><subject>HIV-1 - enzymology</subject><subject>HIV-1 - growth &amp; development</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Polyhydroxylated aromatics</subject><subject>QSAR studies</subject><subject>Virus Replication - drug effects</subject><issn>0968-0896</issn><issn>1464-3391</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpF0d2O1CAUB3BiNO44-gDeGG40mkxHWmgLeqUbdTfZxBv1llA4dZi00AWm2fo2vqk0O2av-MjvnHD4I_SyJPuSlM37474b9b4ihObznpD6EdqUrGEFpaJ8jDZENLwgXDQX6FmMR0JIxUT5FF1kJNqW1xv0t9o1xWcb39Id29VFCvawmODvlg7cn2VYDDh4hw0EO6tkZ4jY91gvevAHuFPOO_iAnZ9hwJNP4BK-uv5VlNi6BL-DipB3B9vZ5EPE6aASngLMD248DclOg9W5uXcZYw3DUHS50mAVo1ric_SkV0OEF-d1i35-_fLj8qq4-f7t-vLTTQEVF6kweVbSsqpqhRBAlNas4pozzTVreFv3HVBOmTZNSyltG9FzZpToe8VqKmqgW_Tmvu8U_O0JYpKjjetrlAN_ipIT0vK1eIteneGpG8HIKdhRhUX-_9QMXp-BiloNfVBO2_jgasqrshXZfbx3kMeaLQQZtQWnwdgAOknjrSyJXKOWR5mjlmvU61WOmv4DIpecGA</recordid><startdate>20040102</startdate><enddate>20040102</enddate><creator>Costi, Roberta</creator><creator>Santo, Roberto Di</creator><creator>Artico, Marino</creator><creator>Massa, Silvio</creator><creator>Ragno, Rino</creator><creator>Loddo, Roberta</creator><creator>La Colla, Massimiliano</creator><creator>Tramontano, Enzo</creator><creator>La Colla, Paolo</creator><creator>Pani, Alessandra</creator><general>Elsevier Ltd</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20040102</creationdate><title>2,6-Bis(3,4,5-trihydroxybenzylydene) derivatives of cyclohexanone: novel potent HIV-1 integrase inhibitors that prevent HIV-1 multiplication in cell-based assays</title><author>Costi, Roberta ; Santo, Roberto Di ; Artico, Marino ; Massa, Silvio ; Ragno, Rino ; Loddo, Roberta ; La Colla, Massimiliano ; Tramontano, Enzo ; La Colla, Paolo ; Pani, Alessandra</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e289t-d968074227999e0acc428c84c8c46875fbe3834cd67333769f84da9ffa45395e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Anti-HIV Agents - chemistry</topic><topic>Anti-HIV Agents - pharmacology</topic><topic>Anti-HIV-1-IN agents</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral agents</topic><topic>Biological and medical sciences</topic><topic>Cell Line, Tumor</topic><topic>Cyclohexanone derivatives</topic><topic>Cyclohexanones - chemistry</topic><topic>Cyclohexanones - pharmacology</topic><topic>HIV Integrase - metabolism</topic><topic>HIV Integrase Inhibitors - chemistry</topic><topic>HIV Integrase Inhibitors - pharmacology</topic><topic>HIV-1 - drug effects</topic><topic>HIV-1 - enzymology</topic><topic>HIV-1 - growth &amp; development</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Polyhydroxylated aromatics</topic><topic>QSAR studies</topic><topic>Virus Replication - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Costi, Roberta</creatorcontrib><creatorcontrib>Santo, Roberto Di</creatorcontrib><creatorcontrib>Artico, Marino</creatorcontrib><creatorcontrib>Massa, Silvio</creatorcontrib><creatorcontrib>Ragno, Rino</creatorcontrib><creatorcontrib>Loddo, Roberta</creatorcontrib><creatorcontrib>La Colla, Massimiliano</creatorcontrib><creatorcontrib>Tramontano, Enzo</creatorcontrib><creatorcontrib>La Colla, Paolo</creatorcontrib><creatorcontrib>Pani, Alessandra</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Bioorganic &amp; medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Costi, Roberta</au><au>Santo, Roberto Di</au><au>Artico, Marino</au><au>Massa, Silvio</au><au>Ragno, Rino</au><au>Loddo, Roberta</au><au>La Colla, Massimiliano</au><au>Tramontano, Enzo</au><au>La Colla, Paolo</au><au>Pani, Alessandra</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>2,6-Bis(3,4,5-trihydroxybenzylydene) derivatives of cyclohexanone: novel potent HIV-1 integrase inhibitors that prevent HIV-1 multiplication in cell-based assays</atitle><jtitle>Bioorganic &amp; medicinal chemistry</jtitle><addtitle>Bioorg Med Chem</addtitle><date>2004-01-02</date><risdate>2004</risdate><volume>12</volume><issue>1</issue><spage>199</spage><epage>215</epage><pages>199-215</pages><issn>0968-0896</issn><eissn>1464-3391</eissn><abstract>A number of 2,6-bisbenzylidenecyclohexane-1-one derivatives have been synthesized and tested as HIV-1 integrase (IN) inhibitors with the aim of obtaining compounds capable to elicit antiviral activity at non-cytotoxic concentrations in cell-based assays. 3,5-Bis(3,4,5-trihydroxybenzylidene)-4-oxocyclohexaneacetic acid (20d) resulted one of the most potent and selective derivatives in acutely infected MT-4 cells (EC50 and CC50 values of 2 and 40 μM, respectively). In enzyme assays with recombinant HIV-1 integrase (rIN), this compound proved able to inhibit both 3′-processing and disintegration with IC50 values of 0.2 and 0.5 μM, respectively. In order to develop a model capable to predict the anti HIV-IN activity and useful to design novel derivatives, we performed a comparative molecular field analysis (CoMFA) like 3-D-QSAR. In our model the ligands were described quantitatively in the GRID program, and the model was optimized by selecting only the most informative variables in the GOLPE program. We found the predictive ability of the model to increase significantly when the number of variables was reduced from 20,925 to 1327. A Q2 of 0.73 was obtained with the final model, confirming the predictive ability of the model. By studying the PLS coefficients in informative 3-D contour plots, ideas for the synthesis of new compounds could be generated. Graphic</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>14697785</pmid><doi>10.1016/j.bmc.2003.10.005</doi><tpages>17</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0968-0896
ispartof Bioorganic & medicinal chemistry, 2004-01, Vol.12 (1), p.199-215
issn 0968-0896
1464-3391
language eng
recordid cdi_proquest_miscellaneous_80078673
source MEDLINE; ScienceDirect Journals (5 years ago - present)
subjects Anti-HIV Agents - chemistry
Anti-HIV Agents - pharmacology
Anti-HIV-1-IN agents
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Biological and medical sciences
Cell Line, Tumor
Cyclohexanone derivatives
Cyclohexanones - chemistry
Cyclohexanones - pharmacology
HIV Integrase - metabolism
HIV Integrase Inhibitors - chemistry
HIV Integrase Inhibitors - pharmacology
HIV-1 - drug effects
HIV-1 - enzymology
HIV-1 - growth & development
Humans
Medical sciences
Pharmacology. Drug treatments
Polyhydroxylated aromatics
QSAR studies
Virus Replication - drug effects
title 2,6-Bis(3,4,5-trihydroxybenzylydene) derivatives of cyclohexanone: novel potent HIV-1 integrase inhibitors that prevent HIV-1 multiplication in cell-based assays
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T01%3A59%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=2,6-Bis(3,4,5-trihydroxybenzylydene)%20derivatives%20of%20cyclohexanone:%20novel%20potent%20HIV-1%20integrase%20inhibitors%20that%20prevent%20HIV-1%20multiplication%20in%20cell-based%20assays&rft.jtitle=Bioorganic%20&%20medicinal%20chemistry&rft.au=Costi,%20Roberta&rft.date=2004-01-02&rft.volume=12&rft.issue=1&rft.spage=199&rft.epage=215&rft.pages=199-215&rft.issn=0968-0896&rft.eissn=1464-3391&rft_id=info:doi/10.1016/j.bmc.2003.10.005&rft_dat=%3Cproquest_pubme%3E80078673%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=80078673&rft_id=info:pmid/14697785&rft_els_id=S0968089603006928&rfr_iscdi=true